Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Aug;21(8):514-525.
doi: 10.1016/j.clml.2021.03.012. Epub 2021 Apr 3.

Chemotherapy Treatments for Burkitt Lymphoma: Systematic Review of Interventional Studies

Ana M Della Rocca  1 , Letícia P Leonart  1 , Vinicius L Ferreira  1 , Fernanda S Tonin  1 , Giovanna Steffenello-Durigon  2 , Joanita A G Del Moral  2 , Fernando Fernandez-Llimos  3 , Roberto Pontarolo  4
Affiliations

Chemotherapy Treatments for Burkitt Lymphoma: Systematic Review of Interventional Studies

Ana M Della Rocca et al. Clin Lymphoma Myeloma Leuk. 2021 Aug.

Abstract

Background: Burkitt lymphoma (BL) is an aggressive hematologic cancer. This study synthetized the evidence about the efficacy and safety of chemotherapy treatments used in patients with BL using the World Health Organization classification.

Materials and methods: A systematic review of interventional studies was performed. A search was carried out in PubMed, Scopus, and Web of Science, with additional manual and gray literature searches. The methodological quality of articles was assessed with the Newcastle-Ottawa scale.

Results: We identified 1358 studies; 9 nonrandomized studies satisfied the eligibility criteria (n = 544 patients). The BL epidemiologic variants were sporadic BL (44.5%), endemic BL (47.2%), and immunodeficiency-associated BL (8.3%). Regarding chemotherapy protocols, 4 groups were identified: based on CODOX-M/IVAC (n = 4), EPOCH (n = 1), BFM (n = 1), and simplified treatment schemes used in African countries (n = 3). Most studies had moderate quality. Empirically and qualitatively, the best options for adults with sporadic BL were 'DA-EPOCH-R' (7-year overall survival [OS], 100%; 95% confidence interval [CI], 82-100), 'HDR + LD into CODOX-M/IVAC' (2-year OS, 84%), and 'RD-CODOX-M/IVAC' (4-year progression-free survival, 92%; 95% CI, 77-100); in pediatric patients, the 'BFM-NHL-90-like' showed promising results (3-year OS, 90%). For immunodeficiency-associated BL, the 'SC-EPOCH-RR' demonstrated a good therapeutic profile (6-year OS, 90%; 95% CI, 60-98). The 'Malawi 2012-2014' (1-year OS, 73%; 95% CI, 61-85) could be the treatment choice in endemic BL (African countries). The main adverse events were hematologic.

Conclusion: Selecting chemotherapy protocols for BL should be grounded in its epidemiologic variants. Further studies with greater methodological quality are needed to strengthen the evidence.

Keywords: Antineoplastic agents; Antineoplastic combined chemotherapy protocols; Hematologic neoplasms; Medical oncology; Treatment outcome.

PubMed Disclaimer

Publication types

Substances